| Literature DB >> 32419982 |
Chiung-Jen Wu1, Kuo-Ho Yeh1, Hui-Ting Wang2, Wen-Hao Liu1, Huang-Chung Chen1, Han-Tan Chai1, Wen-Jung Chung1, Shukai Hsueh1, Chien-Jen Chen1, Hsiu-Yu Fang1, Yung-Lung Chen1.
Abstract
BACKGROUND: The impact of electrocardiography (ECG) morphology on clinical outcomes in patients with non-ST segment elevation myocardial infarction (NSTEMI) receiving percutaneous coronary intervention (PCI) is unknown. This study investigated whether different ST morphologies had different clinical outcomes in patients with NSTEMI receiving PCI.Entities:
Keywords: Clinical outcomes; Electrocardiographic morphology; Non-ST segment elevation myocardial infarction; Percutaneous coronary intervention; ST depression
Year: 2020 PMID: 32419982 PMCID: PMC7211404 DOI: 10.7717/peerj.8796
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Baseline characteristics, angiographic findings and clinical outcomes of 362 study patients according to the presenting ECG.
| Variables | No ST changes ( | Inverted T wave ( | ST depression ( | |
|---|---|---|---|---|
| Age (yrs) | 64.7 ± 12.2 | 65.2 ± 13.4 | 68.8 ± 10.3 | 0.059 |
| Male gender | 77.5% (158) | 68.1% (62) | 65.7% (44) | 0.084 |
| Current smoker | 24.0% (49) | 28.6% (26) | 17.9% (12) | 0.301 |
| Hypertension | 74.5% (152) | 70.3% (64) | 76.1% (51) | 0.669 |
| Diabetes mellitus | 46.1% (94)a | 35.2% (32)a | 52.2% (35)b | 0.080 |
| Dyslipidemia | 38.7% (79) | 36.3% (33) | 37.3% (25) | 0.918 |
| Old stroke | 16.2% (33) | 22.0% (20) | 19.4% (13) | 0.473 |
| Old MI | 8.8% (18)a | 17.6% (16)b | 17.9% (12)b | 0.042 |
| Advanced CKD | 40.2% (82)a | 44.0% (40)a | 65.7% (44)b | <0.001 |
| PVD | 3.4% (7) | 4.4% (4) | 7.5% (5) | 0.379 |
| Prior PTCA | 15.2% (31) | 13.2% (12) | 23.9% (16) | 0.161 |
| Prior CABG | 0% (0)a | 3.3% (3)b | 6.0% (4)b | 0.005 |
| BMI (kg/m2) | 25.4 ± 3.6a | 24.1 ± 3.4b | 25.2 ± 3.6ab | 0.020 |
| Advanced Killip score | 12.7% (26)a | 19.8% (18)ab | 32.8% (22)b | 0.001 |
| LVEF (%) | 60.7 ± 12.3 | 59.3 ± 14.6 | 56.2 ± 15.3 | 0.070 |
| Creatinine level (mg/dl) | 1.33 ± 1.07a | 1.26 ± 0.85a | 1.87 ± 1.70b | 0.002 |
| eGFR (ml/min/1.73m2) | 68.1 ± 28.7a | 66.6 ± 28.5a | 51.2 ± 25.3b | <0.001 |
| Troponin-I (ng/ml) | 9.88 ± 24.6ab | 7.4 ± 9.8b | 19.4 ± 50.0a | 0.025 |
| CAG/PTCA finding | ||||
| Time to angiography | 0.654 | |||
| <24 h | 38.7% (79) | 45.1% (41) | 37.3% (25) | |
| 24–48 h | 12.7% (26) | 12.1% (11) | 17.9% (12) | |
| 48–72 h | 48.5% (99) | 42.9% (39) | 44.8% (30) | |
| Significant CAD | 89.2% (182) | 84.6% (77) | 82.1% (55) | 0.259 |
| Multiple-vessel disease | 67.2% (137) | 62.6% (57) | 71.6% (48) | 0.489 |
| LM | 9.8% (20)a | 12.1% (11)a | 25.4% (17)b | 0.005 |
| Total stent number | 1.6 ± 1.1 | 1.5 ± 1.1 | 1.8 ± 1.4 | 0.255 |
| Stent type | 0.277 | |||
| Drug eluting stent | 45.6% (93) | 48.4% (44) | 34.3% (23) | |
| Bare metal stent | 43.6% (89) | 37.4% (34) | 47.8% (32) | |
| Final TIMI-3 flow | 98.0% (200) | 98.9% (90) | 100.0% (67) | 0.474 |
| Complete revascularization | 93.1% (190) | 93.4% (85) | 89.6% (60) | 0.585 |
| Medication | ||||
| Aspirin | 81.9% (167)a | 79.1% (72)a | 70.1% (47)b | 0.124 |
| Clopidogrel | 89.7% (183)a | 81.3% (74)b | 85.1% (57)ab | 0.132 |
| ACEI/ARB | 70.1% (143) | 64.8% (59) | 61.2% (41) | 0.350 |
| Beta-blocker | 63.7% (130) | 68.1% (62) | 56.7% (38) | 0.337 |
| Statin | 56.9% (116) | 54.9% (50) | 56.7% (38) | 0.952 |
| In-hospital events | ||||
| Total mortality | 2.9% (6)a | 1.1% (1)a | 9.0% (6)b | 0.024 |
| Cardiac death | 2.5 (5)a | 0% (0)a | 7.5% (5)b | 0.017 |
| VT/VF | 2.9% (6) | 2.2% (2) | 4.5% (3) | 0.706 |
| PE | 17.2% (35)a | 18.7% (17)a | 46.3% (31)b | <0.001 |
| Long-term outcome | ||||
| Follow-up duration (months) | 69.7 ± 43.9a | 72.1 ± 43.8a | 48.0 ± 41.2b | 0.001 |
| Total mortality | 15.2% (31)a | 8.8% (8)a | 31.3% (21)b | 0.001 |
| Cardiac death | 7.4% (15)a | 0.0% (0)b | 14.9% (10)c | 0.001 |
| MACE | 31.9% (65) | 35.2% (32) | 32.8% (22) | 0.856 |
| TVR | 14.2% (29) | 12.1% (11) | 13.4% (9) | 0.885 |
| MI | 9.3% (19) | 13.2% (12) | 9.0% (6) | 0.556 |
| Stroke | 4.9% (10) | 5.5% (5) | 4.5% (3) | 0.956 |
| Heart failure | 9.8% (20) | 9.9% (9) | 13.4% (9) | 0.686 |
Notes.
Data are expressed as means ± SD or % (n).
angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers
body mass index
coronary artery bypass surgery
coronary angiography
electrocardiogram
estimated glomerular filtration rate
end stage renal disease
heart failure
left ventricular ejection fraction
major adverse cardiac event
myocardial infarction
percutaneous cardiac intervention
pulmonary edema
percutaneous transluminal coronary angioplasty
peripheral vascular disease
thrombolysis in myocardial infarction
target vessel revascularization
ventricular fibrillation
ventricular tachycardia
eGFR < 60 ml/min/1.73 m2.
Killip score ≥ 3.
Target vessel revascularization, myocardial infarction, stroke and hospitalization for heart failure.
Different letters (a, b, c, i.e.,a vs. b, vs.c) indicate significant difference between groups (P < 0.05).
Baseline characteristics, angiographic findings and clinical outcomes of 362 study patients with and without long term mortality.
| Variables | Mortality ( | Alive ( | |
|---|---|---|---|
| Age (yrs) | 71.4 ± 9.4 | 64.4 ± 12.4 | <0.001 |
| Male gender | 65.0% (39) | 74.5% (225) | 0.130 |
| Current smoker | 16.7% (10) | 25.5% (77) | 0.185 |
| Hypertension | 78.3% (47) | 72.8% (220) | 0.425 |
| Diabetes mellitus | 60.0% (36) | 41.4% (125) | 0.010 |
| Dyslipidemia | 38.3% (23) | 37.7% (114) | 0.932 |
| Old stroke | 23.3% (14) | 17.2% (52) | 0.263 |
| Old myocardial infarction | 13.3% (8) | 12.6% (38) | 0.873 |
| Prior PTCA | 28.3% (17) | 13.9% (42) | 0.006 |
| Prior CABG | 1.7% (1) | 2.0% (6) | 1.000 |
| Peripheral vascular disease | 8.3% (5) | 3.6% (11) | 0.106 |
| Advanced CKD | 66.7% (40) | 41.7% (126) | 0.001 |
| Body mass index (kg/m2) | 25.1 ± 3.8 | 25.0 ± 3.5 | 0.932 |
| Advance Killip score | 43.3% (26) | 13.2% (40) | <0.001 |
| Troponin-I | 19.6 ± 52.5 | 9.3 ± 21.2 | 0.137 |
| LVEF | 54.5 ± 13.9 | 60.5 ± 13.5 | 0.003 |
| Time to angiography | 0.177 | ||
| <24 h | 30.0% (18) | 42.1% (127) | |
| 24–48 h | 18.3% (11) | 12.6% (38) | |
| 48–72 h | 51.7% (31) | 45.4% (137) | |
| ECG changes | <0.001 | ||
| ST depression | 35.0% (21) | 15.2% (46) | |
| No ST depression | 65.0% (39) | 84.8% (256) | |
| Multiple-vessel disease | 66.7% (40) | 66.9% (202) | 0.974 |
| Left main disease | 20.0% (12) | 11.9% (36) | 0.092 |
| Total stent number | 1.4 ± 1.0 | 1.3 ± 0.7 | 0.326 |
| Stent type | 0.407 | ||
| Drug eluting stent | 36.7% (22) | 45.7% (138) | |
| Bare metal stent | 50.0% (30) | 41.4% (125) | |
| Post-PCI TIMI-3 flow | 96.7% (58) | 99.0% (299) | 0.156 |
| Complete revascularization | 91.7% (55) | 92.7% (280) | 0.778 |
Notes.
Data are expressed as means ± SD or % (n).
coronary artery bypass surgery
chronic kidney disease
electrocardiogram
end stage renal disease
Left Ventricular Ejection fraction
percutaneous cardiac intervention
percutaneous transluminal coronary angioplasty
Thrombolysis in Myocardial Infarction
Estimated glomerular filtration rate < 60 ml/min/1.73 m2.
Killip score ≥ 3.
Univariate and multivariate analysis of predictors for long-term mortality.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Advanced Killip score | 5.436 (3.232–9.143) | <0.001 | 3.417 (1.966–5.939) | <0.001 |
| Age (year) | 1.065 (1.039–1.093) | <0.001 | 1.043 (1.015–1.072) | 0.002 |
| Prior PTCA | 2.443 (1.391–4.293) | 0.002 | 1.987 (1.110–3.558) | 0.021 |
| Advanced CKD | 2.782 (1.670–4.636) | <0.001 | 1.871 (1.044–3.354) | 0.035 |
| ST depression | 3.113 (1.826–5.308) | <0.001 | 1.809 (1.015–3.223) | 0.044 |
| LM disease | 2.516 (1.326–4.775) | 0.005 | 1.919 (1.069–3.445) | 0.094 |
| DM | 2.067 (1.232–3.467) | 0.006 | 1.083 (0.611–1.922) | 0.784 |
| LVEF (%) | 0.967 (0.950–0.985) | <0.001 | 1.002 (0.981–1.023) | 0.868 |
Notes.
confidence interval
chronic kidney disease
diabetes mellitus
hazard ratio
left main
left ventricular ejection fraction
percutaneous transluminal coronary angioplasty
Killip score ≥ 3.
Estimated glomerular filtration rate < 60 ml/min/1.73 m2.
Figure 1Kaplan–Meier estimates of total mortality among patients with different ST segment morphology on the presenting electrocardiography.
(A) Kaplan–Meier estimates of total mortality among patients with and without ST depression on the presenting electrocardiography. The analysis reveals that the overall survival rate at 66 months was significantly lower in the ST depression group than in the no-ST depression group (69.7% versus 88.5%, Log-rank P value < 0.001). (B) Kaplan–Meier estimates of total mortality among patients with no significant ST-T change, ST depression and T wave inversion on presenting electrocardiography. The analysis reveals that the overall survival rate at 66 months was significantly lower in the ST depression group than in the no significant ST-T change and T wave inversion group (69.7% versus 87.4% versus 91.0%, Log-rank P value < 0.001).
Figure 2Kaplan–Meier estimates of cardiac death among patients with different ST segment morphology on the presenting electrocardiography.
(A) Kaplan–Meier estimates of cardiac death among patients with and without ST depression on the presenting electrocardiography. The analysis reveals that the freedom from cardiac death rate at 66 months was significantly lower in the ST depression group than in the no-ST depression group (87.4% versus 95.1%, Log-rank P value =0.001). (B) Kaplan–Meier estimates of cardiac death among patients with no significant ST-T change, ST depression and T wave inversion on the presenting electrocardiography. The analysis reveals that the freedom from cardiac death rate at 66 months was significantly lower in the ST depression group than in the no significant ST-T change and T wave inversion group (87.4% versus 93.0% versus 100%, Log-rank P value < 0.001).
Figure 3Kaplan–Meier estimates of non-fatal major adverse cardiac events (MACE) among patients with different ST segment morphology on the presenting electrocardiography.
(A) Kaplan–Meier estimates of non-fatal MACE, which were defined as target vessel revascularization, myocardial infarction, stroke, and hospitalization for heart failure, among patients with and without ST depression on the presenting electrocardiography. The analysis illustrates that there was no difference in the freedom from non-fatal MACE rate at 66 months among patients with ST depression and no-ST depression ECG patterns (61.7% versus 65.6%, Log-rank P value =0.228). (B) Kaplan–Meier estimates of non-fatal MACE among patients with no significant ST-T change, ST depression and T wave inversion on the presenting electrocardiography. The analysis reveals that there were no differences in non-fatal MACE among patients with ST depression, no significant ST-T changes and T wave inversion (61.7% versus 64.9% versus 67.2%, Log-rank P value = 0.482).